The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Value
|
81 | 75 | 73 | 83 |
|
Growth
|
63 | 67 | 79 | 37 |
|
Safety
|
38 | 41 | 43 | 81 |
|
Sentiment
|
38 | 59 | 53 | 33 |
|
360° View
|
56 | 73 | 84 | 67 |
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Analyst Opinions
|
73 | 64 | 64 | 74 |
|
Opinions Change
|
57 | 37 | 53 | 50 |
|
Pro Holdings
|
n/a | 72 | 45 | 16 |
|
Market Pulse
|
21 | 18 | 38 | 35 |
|
Sentiment
|
38 | 59 | 53 | 33 |
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Value
|
81 | 75 | 73 | 83 |
|
Growth
|
63 | 67 | 79 | 37 |
|
|
38 | 41 | 43 | 81 |
|
Combined
|
76 | 83 | 85 | 91 |
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Price vs. Sales (P/S)
|
87 | 81 | 82 | 89 |
|
Price vs. Earnings (P/E)
|
77 | 73 | 82 | 87 |
|
Price vs. Book (P/B)
|
80 | 73 | 80 | 86 |
|
Dividend Yield
|
33 | 39 | 34 | 36 |
|
Value
|
81 | 75 | 73 | 83 |
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Revenue Growth
|
64 | 56 | 38 | 33 |
|
Profit Growth
|
36 | 42 | 88 | 58 |
|
Capital Growth
|
95 | 52 | 29 | 84 |
|
Stock Returns
|
25 | 73 | 100 | 7 |
|
Growth
|
63 | 67 | 79 | 37 |
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Leverage
|
29 | 32 | 40 | 42 |
|
Refinancing
|
86 | 78 | 82 | 90 |
|
Liquidity
|
23 | 38 | 40 | 76 |
|
|
38 | 41 | 43 | 81 |
Discover high‑ranked alternatives to Aurobindo Pharma and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.
30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.